These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19689280)

  • 21. Heparin monitoring: clinical outcome and practical approach.
    Despas N; Larock AS; Jacqmin H; Douxfils J; Chatelain B; Chatelain M; Mullier F
    Ann Biol Clin (Paris); 2016 Dec; 74(6):637-652. PubMed ID: 27848915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulant activity and pleiotropic effects of heparin.
    Bal Dit Sollier C; Dillinger JG; Drouet L
    J Med Vasc; 2020 May; 45(3):147-157. PubMed ID: 32402428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation.
    Spadarella G; Di Minno A; Donati MB; Mormile M; Ventre I; Di Minno G
    Blood Rev; 2020 Jan; 39():100613. PubMed ID: 31471127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.
    Gerotziafas GT; Galea V; Mbemba E; Sassi M; Roman MP; Khaterchi A; van Dreden P; Japcowitz M; Lotz JP; Bernaudin JF; Fareed J; Hatmi M; Elalamy I
    Curr Vasc Pharmacol; 2014; 12(6):893-902. PubMed ID: 22724467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
    Heaton D; Pearce M
    Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?
    Boneu B
    Thromb Res; 2000 Oct; 100(2):V113-20. PubMed ID: 11053624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-molecular-weight heparin for the treatment of venous thromboembolism.
    Hirsh J
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S336-42. PubMed ID: 9628447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis.
    van den Boom BP; von Meijenfeldt FA; Adelmeijer J; Roberts LN; Bernal W; Lisman T
    J Thromb Haemost; 2021 Jun; 19(6):1472-1482. PubMed ID: 33725411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Traditional anticoagulant therapy: why abandon half a century of success?
    Bussey H
    Am J Health Syst Pharm; 2002 Oct; 59(20 Suppl 6):S3-6. PubMed ID: 12400243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
    Masuko S; Linhardt RJ
    Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
    Baluwala I; Favaloro EJ; Pasalic L
    Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.